Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06840262 · ClinicalTrials.gov registry record · NA
Target Muscle Re-innervation and Regenerative Peripheral Nerve Interfaces Alone and in Combination for the Treatment of Residual and Phantom Limb Pain in Cancer Patients Who Have Received an Amputation
A NA study of Amputation, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06840262: Recruiting NA study of Amputation, sponsored by M.D. Anderson Cancer Center.
NCT06840262 is a NA study of Amputation that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 45 participants, below the 132-participant average among 65 other Amputation trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06840262, a NA study of Amputation, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial evaluates two surgical techniques (targeted muscle re-innervation \[TMR\] and regenerative peripheral nerve interfaces \[RPNI\]) alone and in combination for the alleviation of chronic residual limb and phantom limb pain in cancer patients who have had an amputation. Chronic residual limb pain and phantom limb pain are debilitating outcomes of traumatic and oncologic amputation. Emerging microsurgical treatments for post-amputation pain are very promising. TMR and RPNI are both approved surgical techniques that involve connecting cut nerves to parts of the muscle as a way to heal and protect the nerves. This trial evaluates these techniques alone and in combination for the treatment of residual and phantom limb pain in cancer patients who have received an amputation.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- PROCEDURE Regenerative Peripheral Nerve Interface Surgery
- PROCEDURE Targeted Muscle Reinnervation
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-08-10 |
| Est. Completion | 2027-02-02 |
| Phase | NA |
What NCT06840262 shows while recruiting
NCT06840262 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 132-participant average among 65 other Amputation trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Amputation appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT06840262 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06840262 about?
NCT06840262 is a clinical study titled "Target Muscle Re-innervation and Regenerative Peripheral Nerve Interfaces Alone and in Combination for the Treatment of Residual and Phantom Limb Pain in Cancer Patients Who Have Received an Amputation". This clinical trial evaluates two surgical techniques (targeted muscle re-innervation \[TMR\] and regenerative peripheral nerve interfaces \[RPNI\]) alone and in combination for the alleviation of chronic residual limb and phantom limb pain in cancer patients who have had an amputation. Chronic resi...
What is the current status of trial NCT06840262?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2020-08-10. Estimated completion is 2027-02-02.
What conditions does trial NCT06840262 study?
This clinical trial studies the following conditions: Amputation.
What interventions are being tested in trial NCT06840262?
The interventions under investigation include: Questionnaire Administration (OTHER), Regenerative Peripheral Nerve Interface Surgery (PROCEDURE), Targeted Muscle Reinnervation (PROCEDURE).
Who is sponsoring clinical trial NCT06840262?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06840262 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amputation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06840262's enrollment target sits among peer trials
45 20th of 65 higher than 45 of 65 other Amputation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amputation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Myoelectric Implantable Recording Array (MIRA) in Participants With Transradial Amputation
RECRUITING · NA
-
Efficacy and Mechanisms of Virtual Reality Treatment of Phantom Leg Pain.Home-Based Treatment
RECRUITING · NA
-
Hand Transplantation
RECRUITING · NA
-
Can an Array of Micro-electrodes Implanted in a Human Nerve Record Neural Signals and Provide Feedback?
RECRUITING · NA
-
Intuitive Control of a Hybrid Prosthetic Leg During Ambulation
RECRUITING · NA
-
Hybrid Pump Technology
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI